Uplizna recommended for approval in EU as treatment for IgG4-RD
An advisory committee of the European Medicines Agency, or EMA — which evaluations medications for drug approval in the European Union — has recommended Uplizna (inebilizumab) for the treatment of adults with active IgG4-related disease (IgG4-RD). The positive opinion from the EMA’s Committee for Medicinal Products for Human…

